Nemaura Medical (NASDAQ:NMRD) and Microbot Medical (NASDAQ:MBOT) Financial Comparison

Nemaura Medical (NASDAQ:NMRD) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and target prices for Nemaura Medical and Microbot Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
Microbot Medical	0	0	1	0	3.00

Microbot Medical has a consensus price target of $9.00, indicating a potential upside of 484.42%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than Nemaura Medical.

Insider & Institutional Ownership

4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by insiders. Comparatively, 5.4% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Nemaura Medical and Microbot Medical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	2.67	-$14.14 million	($0.39)	0.00
Microbot Medical	N/A	N/A	-$10.74 million	($0.80)	-1.93

Microbot Medical has lower revenue, but higher earnings than Nemaura Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Nemaura Medical has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares Nemaura Medical and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
Microbot Medical	N/A	-218.30%	-158.17%

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.